Diacron reactive oxygen metabolites and biological antioxidant potential tests for patients with age-related macular degeneration

Matsuura, Tamifusa; Kaneko, Hiroki; Takayama, Kei; Shibata, Rei; Kataoka, Keiko; Ito, Shigemitsu; Tsunekawa, Taku; Shimizu, Hideyuki; Suzumura, Ayana; Namba, Rina; Ito, Yasuki; Murohara, Toyoaki; Terasaki, Hiroko

doi:10.21203/rs.2.9800/v2

Cited by 2 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The analysis of comparison between the genders revealed the d-ROMs was significantly higher in women. This result agrees with other studies carried out in healthy individuals (47) and individuals with various pathologies (35,43,46,49,59,66). One of the possible explanations for this result is the hormonal changes in women associated with blood concentrations of estrogen and, therefore, on menopausal status (46).…”

Section: Discussionsupporting

confidence: 93%

“…Numerous studies have demonstrated the usefulness and effectiveness of the evaluation of the redox state through these two tests, both in the evaluation in humans and in animals (11,14,36,42,43,47,(58)(59)(60) however, this is the first time that there was a correlation investigation of both parameters with a wide range of hematological and biochemical variables.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Characterization of the redox status of cancer patients through the d-ROMs and BAP test and correlation of these parameters with blood variables

Oliveira¹,

Iorio²,

Paraíso³

et al. 2023

Preprint

View full text Add to dashboard Cite

Oxidative distress and inflammation are common biochemical disorders in individuals with cancer. The measurement of oxidative stress in oncology can be useful in clinical practice to monitor the effectiveness of therapy and unwanted effects of the treatment. Thus, the aim of the present study was to evaluate the redox status through the reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) tests and investigate the correlations of these parameters with blood variables in cancer patients. This is an observational, retrospective study of analysis of medical records of patients evaluated the period from 2018 to 2020 in an integrative medicine center. The inclusion criteria were individuals of both sexes, over 18 years of age, diagnosed with cancer who performed the d-ROMs and BAP test in the same period of blood analysis. Following the inclusion criteria, the final sample of the study were 57 individuals, 60% were woman and 40% were men. The evaluation of redox state showed that the d-ROMs were high (420.2 ± 112.1 U CARR) in total sample and higher in women compared to male (p < 0.01) and BAP tests were normal (2332 ± 812 μmol/l). The oxidative parameters, d-ROMs and OSI, was correlated positively with BAP, red cell distribution width (only d-ROMs), platelets (Plt), C-reactive protein (CRP), erythrocyte sedimentation (ESR) and negatively with hemoglobin (Hb) and mean corpuscular hemoglobin (MCH). Regarding the antioxidant potential index, BAP/dROMs, were correlated positively with Hb and serum albumin (HAS) and negatively correlated with Plt, CRP and ESR. The study shows that redox status of an individual with cancer is altered, and it is possible to monitor this system in clinical practice through d-ROMs and BAP test. These parameters, in addition to being suitable for assessing oxidative stress, were correlated with parameters predictors of inflammation.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Characterization of the redox status of cancer patients through the d-ROMs and BAP test and correlation of these parameters with blood variables

Oliveira¹,

Iorio²,

Paraíso³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The biological antioxidant potential (BAP) level was measured as a marker of oxidative stress. Measurement of the BAP concentrations (Diacron International, Grosseto, Italy) was performed using a spectrophotometer, as reported previously [51].…”

Section: Biochemical Evaluationmentioning

confidence: 99%

A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease

et al. 2022

View full text Add to dashboard Cite

Background Currently, there is no approved medication for non-alcoholic fatty liver disease management. Pre-clinical and clinical studies showed that several bioactive molecules in plants or foods (i.e., curcumin complex, bergamot polyphenol fraction, artichoke leaf extract, black seed oil, concentrate fish oil, picroliv root, glutathione, S-adenosyl-l-methionine and other natural ingredients) have been associated with improved fatty liver disease. Starting from these evidences, our purpose was to evaluate the effects of a novel combination of abovementioned nutraceuticals as a treatment for adults with fatty liver disease. Methods A total of 140 participants with liver steatosis were enrolled in a randomized, double-blind, placebo controlled clinical trial. The intervention group received six softgel capsules daily of a nutraceutical (namely Livogen Plus®) containing a combination of natural bioactive components for 12 weeks. The control group received six softgel capsules daily of a placebo containing maltodextrin for 12 weeks. The primary outcome measure was the change in liver fat content (CAP score). CAP score, by transient elastography, serum glucose, lipids, transaminases, and cytokines were measured at baseline and after intervention. Results After adjustment for confounding variables (i.e., CAP score and triglyceride at baseline, and changes of serum γGT, and vegetable and animal proteins, cholesterol intake at the follow-up), we found a greater CAP score reduction in the nutraceutical group rather than placebo (− 34 ± 5 dB/m vs. − 20 ± 5 dB/m, respectively; p = 0.045). The CAP score reduction (%) was even greater in those with aged 60 or less, low baseline HDL-C, AST reduction as well as in men. Conclusion Our results showed that a new combination of bioactive molecules as nutraceutical was safe and effective in reducing liver fat content over 12 weeks in individuals with hepatic steatosis. Trial registration ISRCTN, ISRCTN70887063. Registered 03 August 2021—retrospectively registered, https://doi.org/10.1186/ISRCTN70887063

show abstract

Diacron reactive oxygen metabolites and biological antioxidant potential tests for patients with age-related macular degeneration

Cited by 2 publications

References 7 publications

Characterization of the redox status of cancer patients through the d-ROMs and BAP test and correlation of these parameters with blood variables

Characterization of the redox status of cancer patients through the d-ROMs and BAP test and correlation of these parameters with blood variables

A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease

Contact Info

Product

Resources

About